HCV Sales Drive AbbVie's Great Quarter, But Gains Won't Last
Executive Summary
Q1 earnings far outpaced expectations due to the successful launch for new hepatitis C drug Mavyret, but with the HCV market overall in decline those gains won't last and won't make up for the looming loss of Humira revenue.
You may also be interested in...
AbbVie HCV Revenue Surprises Again, But Falloff Is Coming
Led by eight-week, pan-genotypic combo Mavyret, AbbVie’s HCV franchise grows despite a declining US market that has taken a toll on competitors Gilead and Merck. Still, AbbVie expects a falloff in the third quarter.
AbbVie HCV Revenue Surprises Again, But Falloff Is Coming
Led by eight-week, pan-genotypic combo Mavyret, AbbVie’s HCV franchise grows despite a declining US market that has taken a toll on competitors Gilead and Merck. Still, AbbVie expects a falloff in the third quarter.
Pharma Q2 Results Preview: Celgene, Amgen, Allergan And AbbVie
With the FDA updating its stance on interchangeability, analysts will be pushing Amgen and AbbVie on how the policy changes will affect biosimilar competition. Celgene and Allergan will be under pressure for R&D updates; Allergan remains in the hot seat on its pipeline growth strategy from activist investors.